In November 2011, Cellectis bioresearch acquired Cellartis. Cellectis bioresearch can now offer stem cell researchers a new and growing product portfolio:

Hepatocytes

Cardiomyocytes

Culture system

Monoclonal antibodies

Mesenshymal progenitors

 

Please contact your local sales representative should you need any further information.

Cellartis, a Swedish company founded in 2001, was formed as a spin-off from the University of Gothenburg. From its inception the company has worked on pluripotent stem cells and technologies for drug discovery research, toxicity testing and regenerative medicine. Cellartis has proven expertise in many different areas including:

• controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
• ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
• effective industrial rollout of their technologies;
• regenerative medicine programs in collaboration with leading global partners, using the immense potential of stem cells for the restoration of damaged tissues and organs.